Unknown

Dataset Information

0

Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.

ABSTRACT: Introduction:Osteoclasts are giant polynuclear cells; their main function is bone resorption. An increased number of osteoclasts and enhanced bone resorption exert significant effects on osteoclast-related bone-lytic diseases, including osteoporosis. Given the limitations of current therapies for osteolytic diseases, it is urgently required to develop safer and more effective alternatives. Sarsasapogenin, a major sapogenin from Anemarrhena asphodeloides Bunge, possesses potent antitumor effects and inhibits NF-?B and MAPK signaling. However, the manner in which it affects osteoclasts is unclear. Methods:We investigated the effects of anti-osteoclastogenic and anti-resorptive of sarsasapogenin on bone marrow-derived osteoclasts. Results:Sarsasapogenin inhibited multiple RANKL-induced signaling cascades, thereby inhibiting the induction of key osteoclast transcription factor NFATc1. The in vivo and in vitro results were consistent: sarsasapogenin treatment protected against bone loss in a mouse osteolysis model induced by lipopolysaccharide. Conclusion:Our research confirms that sarsasapogenin can be used as a new treatment for osteoclast-related osteolytic diseases.

SUBMITTER: Peng J 

PROVIDER: S-EPMC7474134 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.

Peng Jiaxuan J   Zhao Kangxian K   Zhu Jiling J   Wang Yanben Y   Sun Peng P   Yang Qichang Q   Zhang Tan T   Han Weiqi W   Hu Wenjun W   Yang Wanlei W   Ruan Jianwei J   Qian Yu Y  

Drug design, development and therapy 20200824

<h4>Introduction</h4>Osteoclasts are giant polynuclear cells; their main function is bone resorption. An increased number of osteoclasts and enhanced bone resorption exert significant effects on osteoclast-related bone-lytic diseases, including osteoporosis. Given the limitations of current therapies for osteolytic diseases, it is urgently required to develop safer and more effective alternatives. Sarsasapogenin, a major sapogenin from <i>Anemarrhena asphodeloides</i> Bunge, possesses potent ant  ...[more]

Similar Datasets

Unknown Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
| S-EPMC3969079 | biostudies-other
Unknown Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption.
| S-EPMC5601052 | biostudies-literature
Unknown Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.
| S-EPMC7898668 | biostudies-literature
Unknown BCI Suppresses RANKL-Mediated Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss.
| S-EPMC8596812 | biostudies-literature
Unknown Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss.
| S-EPMC4559750 | biostudies-literature
Unknown Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice.
| S-EPMC6307789 | biostudies-literature
Unknown Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice.
| S-EPMC6987431 | biostudies-literature
Unknown Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo.
| S-EPMC4523876 | biostudies-literature
Unknown Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss.
| S-EPMC7994615 | biostudies-literature
Unknown Dual targeting of SREBP2 and ERRα by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss.
| S-EPMC7308277 | biostudies-literature